> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Nixes Lilly/Boehringer Diabetes Drug
- URL: https://www.fdaweb.com/panel-nixes-lilly-boehringer-diabetes-drug/
- Published: 2019-11-14T12:00:00.000Z
- Updated: 2026-09-14T15:53:06.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145510

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee has voted 14 to 2 to not recommend approval of Eli Lilly and Boehringer Ingelheim’s empagliflozin 2.5 mg because the drug’s benefits do not outweigh its risks as an adjunct to insulin for adults with Type 1 diabetes. The SGLT2 inhibitor is currently approved as Jardiance in 10 mg and 20 mg for lowering blood sugar levels in patients with Type 2 diabetes. The companies note that a separate brand name has been proposed for empagliflozin 2.5 mg in type 1 diabetes.

Panel members expressed concern that SGLT2 inhibitors have been associated with risks of diabetic ketoacidosis (DKA) in higher doses. DKA occurs when the body starts breaking down fat at a rate that is much too fast. The liver processes the fat into a fuel called ketones, which causes the blood to become acidic. The panel recommended an additional study to determine safety risks.